Molecular Diagnosis & Therapy

, Volume 11, Issue 3, pp 193–201 | Cite as

Telomerase Activity as a Tumor Marker in Indian Women with Cervical Intraepithelial Neoplasia and Cervical Cancer

  • Alpana Sharma
  • Medha Rajappa
  • Alpana Saxena
  • Manoj Sharma
Original Research Article


Background and objectives: Cervical cancer is the most common cancer in Indian women and is a leading cause of death in women worldwide. Cervical cancer develops from pre-neoplastic cervical intraepithelial neoplasia (CIN). This study was conducted to evaluate telomerase activity as a tumor marker for the detection of cancer in patients with CIN and cervical cancer. The results were compared with human papillomavirus (HPV) status, clinical staging, and histopathologic studies.

Methods: Telomerase activity was detected using the PCR-based telomeric repeat amplification protocol (TRAP) assay in cervical tissues collected by routine punch biopsy from the uterine cervix of patients with suspected cervical cancer. High-risk (HR) HPV-16 and -18 status was determined in all the study groups, including controls. A total of 125 patients (including 50 patients with CIN and 75 patients with cervical cancer [including nine patients with adeno-squamous disease]) and 22 control subjects were studied. The sensitivity and specificity for detecting CIN and cervical cancer were calculated.

Results: Patients with grade I, II, and III CIN showed 17%, 33%, and 57% positivity for telomerase, respectively. In patients with cervical cancer, those at early clinical stages (Ia-IIb) showed 68% positivity and those at later clinical stages showed 92% positivity for telomerase activity. In the present study, telomerase positivity correlated significantly with the detection of HR HPV-16 and -18 (p < 0.001). As a diagnostic test, none of the described analyses combined a sensitivity of ≥90% with a specificity of ≥90%, except in patients with advanced cancer when telomerase activity was used as a diagnostic test.

Conclusion: Our findings suggest that telomerase activation is a relatively early event in cervical carcinogenesis and correlates with the grade of cervical lesion, HR-HPV status (16 and 18 subtypes), and clinical staging. Hence, these associations suggest it as a possible target for detection of cervical cancer.


Cervical Cancer Cervical Intraepithelial Neoplasia Telomeric Repeat Amplification Protocol Telomeric Repeat Amplification Protocol Cervical Intraepithelial Neoplasia Grade 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



We thank Dr B.C. Das and Dr Uma Kailash, Institute of Cytology and Preventive Oncology, New Delhi, India, and Dr Raksha Arora, Department of Obstetrics and Gynecology, Maulana Azad Medical College and Associated Hospitals, New Delhi, India, for their help during the course of this study.

We are particularly indebted to the patients who agreed to participate in this study. The financial support provided by the Indian Council of Medical Research, New Delhi is gratefully acknowledged. The authors have no conflicts of interest that are directly relevant to the content of this study.


  1. 1.
    National Cancer Registry Programme. Consolidated report of the population based cancer registries. New Delhi: ICMR, 1996: 61Google Scholar
  2. 2.
    Herrero R. Epidemiology of cervical cancer. Natl Cancer Inst Monogr 1996; 21: 1–6Google Scholar
  3. 3.
    Pisani M, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985: implications for prevention and projections of future burden. Int J Cancer 1993; 55: 891–903PubMedCrossRefGoogle Scholar
  4. 4.
    Pinto AP, Cram CP. Natural history of cervical neoplasia: defining progression and its consequences. Clin Obstet Gynaecol 2000; 43: 352–62CrossRefGoogle Scholar
  5. 5.
    Ault KA, Allen HK, Phillips SL, et al. Telomerase activity as a potential diagnostic marker for triage of abnormal Pap smears. J Low Genit Tract Dis 2005; 9: 93–9PubMedCrossRefGoogle Scholar
  6. 6.
    Bravaccini S, Sanchini MA, Amadori A, et al. Potential of telomerase expression and activity in cervical specimens as a diagnostic tool. J Clin Pathol 2005; 58: 911–4PubMedCrossRefGoogle Scholar
  7. 7.
    Reddy VG, Khanna N, Jain SK, et al. Telomerase: a molecular marker for cervical cancer screening. Int J Gynecol Cancer 2001; 11: 100–6PubMedCrossRefGoogle Scholar
  8. 8.
    Blackburn EH. Structure and function of telomeres. Nature 1991 Apr 18; 350(6319): 569–73PubMedCrossRefGoogle Scholar
  9. 9.
    Zheng PS, Iwasaka T, Zhang ZH, et al. Telomerase activity in Papanicalou smear-negative exfoliated cervical cells and its association with lesions and oncogenic human papilloma viruses. Gynecol Oncol 2000; 77: 394–8PubMedCrossRefGoogle Scholar
  10. 10.
    Reesink Peters N, Helder MN, Wisman GBA, et al. Detection of telomerase, its components and human papilloma virus in cervical scrapings as a tool for triage in women with cervical dysplasia. J Clin Pathol 2003; 56: 31–5CrossRefGoogle Scholar
  11. 11.
    Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin-Phenol reagent. J Biol Chem 1951; 193: 265–75PubMedGoogle Scholar
  12. 12.
    Kim NW, Piatyszak MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011–4PubMedCrossRefGoogle Scholar
  13. 13.
    Kyo S, Kanaya T, Ishikawa H, et al. Telomerase activity in gynaecological tumors. Clin Cancer Res 1996; 2: 2023–8PubMedGoogle Scholar
  14. 14.
    Boom R, Sol CJA, Salimans MMM, et al. Rapid and simple detection method for purification of nucleic acids. J Clin Microbiol 1990; 28: 495–503PubMedGoogle Scholar
  15. 15.
    Smits HL, Tieben LM, Tjong-A-Hung SP, et al. Detection and typing of human papilloma viruses present in fixed and stained archival cervical smears by a consensus polymerase chain reaction and direct sequencing allow the identification of a broad spectrum of human papilloma viras types. J Gen Virol 1992; 73: 3263–8PubMedCrossRefGoogle Scholar
  16. 16.
    Tieben LM, ter Schegget J, Minaar RP. Detection of cutaneous and genital HPV types in clinical samples by PCR using consensus primers. J Virol Methods 1993; 42: 265–80PubMedCrossRefGoogle Scholar
  17. 17.
    Wisman GB, de Jong S, Meersma GJ, et al. Telomerase in (pre)neoplastic cervical disease. Hum Pathol 2000; 31: 1304–12PubMedCrossRefGoogle Scholar
  18. 18.
    Zheng PS, Iwasaka T, Yamasaki F, et al. Telomerase activity in gynecologic tumors. Gynaecol Oncol 1997; 64: 171–5CrossRefGoogle Scholar
  19. 19.
    Zheng PS, Iwasaka T, Yokoyama H, et al. Telomerase activation in in vitro and in vivo cervical carcinogenesis. Gynecol Oncol 1997; 66: 222–6PubMedCrossRefGoogle Scholar
  20. 20.
    Iwasaka T, Zheng PS, Yokoyama H, et al. Telomerase activation in cervical neoplasia. Obstet Gynecol 1998; 91: 260–7PubMedCrossRefGoogle Scholar
  21. 21.
    Healy KC. Telomerase dynamics and telomerase activation in tumor progression: prospects for prognosis and therapy. Oncol Res 1995; 7: 121–30PubMedGoogle Scholar
  22. 22.
    Wang SZ, Sun JH, Zhang W, et al. Telomerase activity in cervical intraepithelial neoplasia. Chin Med J (Engl) 2004; 117: 202–6Google Scholar
  23. 23.
    Wisman GBA, Knol AJ, Helder MN, et al. Telomerase in relation to clinicopathologic prognostic factors and survival in cervical cancer. Int J Cancer 2001; 91: 658–64PubMedCrossRefGoogle Scholar
  24. 24.
    Schaffer P, Sancho-Garnier H, Fender M, et al. Cervical cancer screening in France. Eur J Cancer 2000; 36: 2215–20PubMedCrossRefGoogle Scholar
  25. 25.
    Sen S, Reddy VG, Guleria R, et al. Telomerase: a potential molecular marker of lung and cervical cancer. Clin Chem Lab Med 2002; 40: 994–1001PubMedCrossRefGoogle Scholar
  26. 26.
    Herbsleb M, Knudsen UB, Orntoft TF, et al. Telomerase activity, MIB-1, PCNA, HPV 16 and p53 as diagnostic markers for cervical intraepithelial neoplasia. APMIS 2001; 109: 607–17PubMedCrossRefGoogle Scholar
  27. 27.
    Zhang DK, Ngan HY, Cheng RY, et al. Clinical significance of telomerase activation and telomeric restriction fragment (TRF) in cervical cancer. Eur J Cancer 1999; 35: 154–60PubMedCrossRefGoogle Scholar
  28. 28.
    Kyo S, Takakura M, Tanaka M, et al. Telomerase activity in cervical cancer is quantitatively different from that in its precursor lesions. Int J Cancer 1998; 79: 66–70PubMedCrossRefGoogle Scholar
  29. 29.
    Yashima K, Ashfaq R, Nowak J, et al. Telomerase activity and expression of its RNA component in cervical lesions. Cancer 1998; 82: 1319–27PubMedCrossRefGoogle Scholar
  30. 30.
    Jarboe EA, Liaw KL, Thompson LC, et al. Analysis of telomerase as diagnostic marker of cervical dysplasia and carcinoma. Oncogene 2002; 21: 664–73PubMedCrossRefGoogle Scholar
  31. 31.
    Nowak JA. Telomerase, cervical cancer and human papilloma virus. Clin Lab Med 2000; 20: 369–82PubMedGoogle Scholar
  32. 32.
    Isaka K, Nishi H, Osakabe Y, et al. Establishment of a HPV and p53-mutation-negative human cell line derived from a squamous carcinoma of the cervix. Gynecol Oncol 2004; 92: 15–21PubMedCrossRefGoogle Scholar
  33. 33.
    Pao CC, Tseng C, Yang F, et al. Differential expression of telomerase activity in human cervical cancer and cervical intraepithelial neoplasia lesions. J Clin Oncol 1997; 15: 1932–7PubMedGoogle Scholar
  34. 34.
    Jarboe EA, Thompson LC, Heinz D, et al. Telomerase and human papilloma virus as diagnostic adjuncts for cervical dysplasia and carcinoma. Hum Pathol 2004; 35: 396–402PubMedCrossRefGoogle Scholar
  35. 35.
    Tsezou A, Oikonomou P, Kollia P, et al. The role of human telomerase catalytic subunit mRNA expression in cervical dysplasias. Exp Biol Med 2005; 230: 263–70Google Scholar
  36. 36.
    Helder MN, de Jong S, de Vries EGE, et al. Telomerase targeting in cancer treatment: new developments. Drug Resist Updat 1999; 2: 104–15PubMedCrossRefGoogle Scholar
  37. 37.
    Novakovic S, Fras PA, Jezersek-Novakovic B. Telomerase activity as a biological marker in some gynaecological tumors. In Vivo 2001; 15: 327–32PubMedGoogle Scholar
  38. 38.
    Norton JC, Piatyszek MA, Wright WE, et al. Inhibition of human telomerase activity by peptide nucleic acids. Nat Biotechnol 1996; 14: 615–9PubMedCrossRefGoogle Scholar
  39. 39.
    Kondo S, Tanka Y, Kondo Y, et al. Antisense telomerase treatment induction of two distinct pathways, apoptosis and differentiation. FASEB J 1998; 12: 801–11PubMedGoogle Scholar
  40. 40.
    Kondo Y, Kondo S, Tanaka Y, et al. Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin induced apoptosis. Oncogene 1998; 16: 2243–8PubMedCrossRefGoogle Scholar
  41. 41.
    Pitts AE, Corey DR. Inhibition of human telomerase by 2′-O-methyl-RNA. Proc Natl Acad Sci U S A 1998; 95: 11549–54PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  • Alpana Sharma
    • 1
  • Medha Rajappa
    • 2
  • Alpana Saxena
    • 3
  • Manoj Sharma
    • 4
  1. 1.Department of BiochemistryAll India Institute of Medical SciencesNew DelhiIndia
  2. 2.Department of Ocular Biochemistry, Dr. R.P. Centre for Ophthalmic SciencesAll India Institute of Medical SciencesNew DelhiIndia
  3. 3.Department of BiochemistryMaulana Azad Medical College and Associated HospitalsNew DelhiIndia
  4. 4.Department of RadiotherapyMaulana Azad Medical College and Associated HospitalsNew DelhiIndia

Personalised recommendations